Laboratory Corporation of America

At the Personalized Medicine Conference this week, stakeholders historically at odds over lab test regulation said it is up to Congress to resolve the issue.

LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.

The new assay simultaneously detects four viral targets in donated blood plasma in a single sample and can add value to the biologics development space.

Under the new agreement, physicians can order both thyroid biopsy analysis and molecular testing from Interpace, and LabCorp's Dianon Pathology, will be available to do biopsy analysis.

Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.

Increased consumer interest in prenatal health is also spurring use of carrier screening for genetic conditions.

The suit filed against the acting HHS secretary alleges that a flawed data collection process failed to establish market-based rates.

Several commercial NIPT providers in the US said they are planning to participate in the new program.

Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.

The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today. 

Pages

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.